載入...
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Primary liver cancer is one of the commonest causes of death. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers. For patients with unresectable or metastatic HCC, conventional chemotherapy is of limited or no benefit. Sorafenib is the only systemic treatment to demonstrate a s...
Na minha lista:
| 發表在: | World J Hepatol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Baishideng Publishing Group Inc
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404384/ https://ncbi.nlm.nih.gov/pubmed/25914779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v7.i5.787 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
載入...